Hims stock jumped late Monday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.

Hims & Hers Health (NYSE:HIMS) shares are moving higher Monday ahead of earnings after the bell. Here’s what you need to know ...

Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.

Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report.

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $20.36 which represents a slight increase of $1.53 or 8.13% from the prior close of $18.83. The stock opened at ...

Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a ...

Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...

Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's ...

Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...

For the fourth quarter, Hims & Hers expects revenue between $465 million and $470 million, above the consensus of $421.1 ...

Needham has recently initiated Hims & Hers Health Inc (HIMS) stock to Buy rating, as announced on August 22, 2024, according to Finviz. Earlier, on August 9, 2024, Imperial Capital had reduced the ...

Hims & Hers is taking a more serious approach to its latest campaign. The telehealth company, which is best known for its ...